Cannabinoid receptor systems: Therapeutic targets for tumour intervention

Expert Opinion on Therapeutic Targets

Volumn 7, Issue 6, 2003, Pages 749-758

  Jones, Sarah ^a   Howl, John ^a  

^a UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

Author keywords

Cannabinoid; Endocannabinoid; Signal transduction; Tumour

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 ARACHIDONOYLGLYCEROL; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; 4 [6 METHOXY 2 (4 METHOXYPHENYL) 3 BENZOFURANYLCARBONYL]BENZONITRILE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ANANDAMIDE; ANTINEOPLASTIC AGENT; BAY 387271; CANNABIDIOL; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AFFECTING AGENT; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CANNABINOL; DELTA8 TETRAHYDROCANNABINOL; DESACETYL LEVO NANTRADIOL; DEXANABINOL; DRONABINOL; G PROTEIN COUPLED RECEPTOR; MEMBRANE RECEPTOR; NOLADIN ETHER; PSYCHOTROPIC AGENT; RIMONABANT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; ASTROCYTOMA; BREAST CANCER; CYTOLOGY; DRUG SYNTHESIS; DRUG TARGETING; GLIOBLASTOMA; HUMAN; LEUKEMIA; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR DYNAMICS; NONHUMAN; PHARMACODYNAMICS; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN FAMILY; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; SKIN CANCER; THYROID CARCINOMA; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARACHIDONIC ACIDS; CANNABINOIDS; CELL LINE, TUMOR; DRUG DESIGN; ENDOCANNABINOIDS; FEMALE; HUMANS; MALE; MAMMALS; MICE; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NERVE TISSUE PROTEINS; POLYUNSATURATED ALKAMIDES; RECEPTORS, CANNABINOID; SIGNAL TRANSDUCTION;

EID: 0346957062     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.7.6.749     Document Type: Review

References (101)

1. MATSUDA LA, LOLAIT SJ, BROWNSTEIN MJ, YOUNG AC, BONNER TI: Structure of a cannabinoid receptor and functional expression of the cloned DNA. Nature (1990) 346:561-564.
2. MUNRO S, THOMAS KL, ABU-SHAAR M: Molecular characterization of a peripheral receptor for cannabinoids. Nature (1993) 365:61-65.
3. BOUABOULA M, POINOT-CHAZEL C, BOURRIE, B et al.: Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor. Biochem. J. (1995) 312:637-641.
4. 2 receptors. Pharmacol. Ther. (1997) 74:129-180.
5. HOWLETT AC, BARTH F, BONNER TI et al.: International union of pharmacology. XXVII. Classification of cannabinoid receptors. Phamacol. Rev. (2002) 54:161-202.
6. DI MARZO V, MELCK D, DE PETROCELLIS D, BISOGNO T: Cannabimimetic fatty acid derivatives in cancer and inflammation. Prostaglandins Other Lipid Mediat. (2000) 61:43-61.
7. KLEIN TW, NEWTON C, LARSEN K et al.: The cannabinoid system and immune modulation. J. Leukoc. Biol. (2003) 74:486-496.
8. ROTH MD, BALDWIN GC, TASHKIN DP: Effects of Δ-9-tetrahydrocannabinol on human immune function and host defense. Chem. Phys. Lipids (2002) 121:229-239.
9. GUZMAN M, SANCHEZ C, GALVE-ROPERH I: Cannabinoids and cell fate. Pharmacol. Ther. (2002) 95:175-184.
10. GUZMAN M, SANCHEZ C, GALVE-ROPERH I: Control of the cell survival/death decision by cannabinoids. J. Mol. Med. (2001) 78:613-625.
11. VAN DER STELT M, VELTHUIS WB, MACCARRONE M et al.: Acute neuronal injury excitotoxicity, and the endocannabinoid system. Mol. Neurobiol. (2002) 26:317-346.
12. GRUNDY RI, RABUFFETTI M, BELTRAMO M: Cannabinoids and neuroprotection. Mol. Neurobiol. (2001) 24:29-52.
13. MECHOULAM R: Discovery of endocannabinoids and some random thoughts on their possible roles in neuroprotection and aggression. Prostaglandins Leukot. Essent. Fatty Acids (2002) 66:93-99.
14. NAGAYAMA T, SINOR AD, SIMON RP et al.: Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J. Neurosci. (1999) 19:2987-2995.
15. BIFULCO M, DI MARZO V: Targeting the endocannabinoid system in cancer therapy: a call for further research. Nature (2002) 8:547-550.
16. PAROLARO D, MASSI P, RUBINO T, MONTI E: Endocannabinoids in the immune system and cancer. Prostaglandins Leukot. Essent. Fatty Acids (2002) 66:319-332.
17. 2 receptor. J. Med. Chem. (1996) 39:3875-3877.
18. 2 receptor. Bioorg. Med. Chem. (1999) 7:2905-2914.
19. (2), a peripheral cannabinoid receptor. Proc. Natl. Acad. Sci. USA (1999) 96:14228-14233.
20. PERTWEE RG, ROSS RA: Cannabinoid receptors and their ligands. Prostaglandins Leukot. Essent. Fatty Acids (2002) 66:101-121.
21. 9-tetrahydrocannabinol. J. Pharmacol. Exp. Ther. (1992) 263:1118-1126.
22. D'AMBRA TE, ESTEP KG, BELL MR et al.: Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective, (aminoalkyl) indole agonists of the cannabinoid receptor. J. Med. Chem. (1992) 35:124-135.
23. EISSENSTAT MA, BELL MR, D'AMBRA TE et al.: Aminoalkylindoles: structure-activity relationships of novel cannabinoid mimetics. J. Med. Chem. (1995) 38:3094-3105.
24. 2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc. Natl. Acad. Sci. USA (2003) 100:10529-10533.
25. MAULER F, MITTENDORF J, HORVATH E, DE VRY J: Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy) phenyl 4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties. J. Pharmacol. Exp. Ther. (2002) 302:359-368.
26. MECHOULAM R, FRIDE E, DI MARZO V: Endocannabinoids. Eur. J. Pharmacol. (1998) 359:1-8.
27. DI MARZO V:'Endocannabinoids' and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. Biochim. Biophys. Acta (1998) 1392:153-175.
28. DEVANE WA, DYSARZ FA, JOHNSON MR et al.: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (1992) 258:1946-1949.
29. 1). J. Pharmacol. Exp. Ther. (1999) 289:1427-1433.
30. MECHOULAM R, BEN-SHABAT S, HANUS S et al.: Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. (1995) 50:83-90.
31. SUGIURA T. KONDO S, SUKAGAWA A et al.: 2-arachidonylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. (1995) 215:89-97.
32. 1 receptor. Proc. Natl. Acad. Sci. USA (2001) 99:3662-3665.
33. OKA S, TSUCHIE A. TOKUMURA A et al.: Ether-linked analogue of 2-arachidonylglycerol (noladin ether) was not detected in the brains of various mammalian species. J Neurochem. (2003) 85:1374-1381.
34. RINALDI-CARMONA M, BARTH F, HEAULME M et al.: SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. (1994) 350:240-244.
35. 1 receptor to stimulation of cAMP accumulation. J. Pharmacol. Exp. Ther. (1998) 284:291-297.
36. BOUABOULA M, PERRACHON S, MILLIGAN L et al.: A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J. Biol. Chem. (1997) 272:22330-22339.
37. 2 cannabinoid receptor. J. Pharmacol. Exp. Ther. (1998) 284:644-650.
38. 2 cannabinoid receptors of L759633, L759656 and AM630. Br. J. Pharmacol. (1999) 126:665-672.
39. PERTWEE RG: Pharmacology of cannabinoid receptor ligands. Curr. Med. Chem. (1999) 6:635-664.
40. DI MARZO V, FONTANA A, CADAS H et al.: Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature (1994) 372:686-691.
41. HILLARD CJ: Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol. Prostaglandins Other Lipid Mediat. (2000) 61:3-18.
42. RAKHSHAN F, DAY TA, BLAKELY RD, BARKER EL: Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3. J. Pharmacol. Exp. Ther. (2000) 292:960-967.
43. BISOGNO T, MAURELLI S, MELCK D, DE PETROCELLIS L, DI MARZO V: Biosynthesis, uptake and degradation of anandamide and palmitoylethanolamide in leukocytes. J. Biol. Chem. (1997) 272:3315-3323.
44. CRAVATT BF, GIANG DK, MAYFIELD SP, BOGER DL, LERNER RA, GILULA NB: Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature (1996) 384:83-87.
45. UEDA N, YAMAMOTO S: Anandamide amidohydrolase (fatty acid amide hydrolase). Prostaglandins Other Lipid Mediat. (2000) 61:19-28.
46. MUNSON AE, HARRIS LS, FRIEDMAN MA, DEWEY WL, CARCHMAN RA. Antineoplastic activity of cannabinoids. J. Natl. Cancer Inst. (1975) 55:597-602.
47. 9-tetrahydrocannabinol in Lewis lung adenocarcinoma cells in tissue culture. J. Natl. Cancer Inst. (1976) 56:655-658.
48. CARCHMAN RA, HARRIS LS, MUNSON AE: The inhibition of DNA synthesis by cannabinoids. Cancer Res. (1976) 31:95-100.
49. 9-tetrahydrocannabinol on cell proliferation and macromolecular biosynthesis in human cells. Biochem. Pharmacol. (1978) 27:1759-1765.
50. MAHER EA. FURNARI FB, BACHOO RM et al.: Malignant glioma: genetics and biology of a grave matter. Genes Dev. (2001) 15:1311-1333.
51. GALVE-ROPERH I, SANCHEZ C, CORTES ML, DEL PULGAR TG, IZQUIERDO M, GUZMAN M: Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat. Med. (2000) 16:313-319.
52. BLAZQUEZ C, CASANOVA ML, PLANAS A et al.: Inhibition of tumor angiogenesis by cannabinoids. FASEB J. (2003) 17:529-531.
53. PUNIGLIA KM, DECKER SJ: Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway. Proc. Natl. Acad. Sci. US4 (1997) 94:448-452.
54. YORK RD, YAO H, DILLON T et al.: Rap1 mediates sustained MAP kinase activation induced by nerve growth factor. Nature (1998) 392:622-626.
55. 9-tetrahydrocannabinol induces apoptosis in C6.9 glioma cells. FEBS Lett. (1998) 436:6-10.
56. 9-tetrahydrocannabinol-induced stimulation of glucose metabolism in primary astrocytes. Mol. Pharmacol. (1998) 54:834-843.
57. PERRY DK, CARTON J, SHAH AK, MEREDITH F, UHLINGER DJ, HANNUN YA. Serine palmitoyltransferase regulates de novo ceramide generation during etoposide-induced apoptosis. J. Biol. Chem. (2000) 275:9078-9094.
58. HUWILER A, KOLTER T, PFEILSCHIFTER J, SANDHOFF K : Physiology and pathophysiology of sphingolipid metabolism and signaling. Biochim. Biophys. Acta (2000) 1485:63-99.
59. GUZMAN M, GALVE-ROPERH I, SANCHEZ C: Ceramide: a new second messenger of cannabinoid action. Trends Pharmacol. Sci. (2001) 22:19-22.
60. BLAZQUEZ C, SANCHEZ C, DAZA A, GALVE-ROPERH I, GUZMAN M: The stimulation of ketogenesis by cannabinoids in cultured astrocytes defines carnitine palmitoyl transferase I as a new ceramide activated enzyme. J. Neurochem. (1999) 72:1759-1768.
61. SANCHEZ C, RUEDA D, SEGUI D, GALVE-ROPERH I, LEVADE T, GUZMAN M: The cannabinoid receptor of astrocytes is coupled to sphingomyelin hydrolysis through the adaptor protein FAN. Mol. Pharmacol. (2001) 59:955-959.
62. 1, cannabinoid receptor is coupled to the activation of protein kinase B/Akt. Biochem. J. (2000) 347:369-373.
63. 1 cannabinoid receptor is coupled to the activation of c-Jun-N-terminal kinase. Mol. Pharmacol. (2000) 58:814-820.
64. HARPER SJ, LOGRASSO P: Signaling for survival and death in neurons. The role of stress-activated kinases, JNK and p38. Cell. Signal. (2001) 13:299-310.
65. 1 cannabinoid receptor. Mol. Pharmacol. (2002) 62:1385-1392.
66. 2 cannabinoid receptor. Cancer Res. (2001) 61:5784-5789.
67. BROWN J, READING SJ, JONES S et al.: Critical evaluation of ECV304 as a human endothelial cell model defined by genetic analysis and functional responses: a comparison with the human bladder cancer derived epithelial cell line T24/83. Lab. Invest. (2000) 80:37-45.
68. DE PETROCELLIS L, MELCK D, PALMISANO A et al.: The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc. Natl. Acad. Sci. USA (1998) 95:8375-8380.
69. MELCK D, DE PETROCELLIS L, ORLANDO P et al.: Suppression of nerve growth factor trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology (2000) 141:118-126.
70. MELCK D, RUEDA D, GALVE-ROPERH I, DE PETROCELLIS L, GUZMAN M, DI MARZO V: Involvement of the cAMP - protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells. FEBS Lett. (1999)463:235-240.
71. CRAVATT BE PROSPER-GARCIA O, SIUZDAK G et al.: Chemical characterization of a family of brain lipids that induce sleep. Science (1995) 268:1506-1509.
72. BISOGNO T, KATAYAMA K, MELCK D et al.: Biosynthesis and degradation of bioactive fatty acid amides in human breast cancer and rat pheochromocytoma cells. Eur. J. Biochem. (1998) 254:634-642.
73. MECHOULAM R, FRIDE E, HANUS L et al.: Anandamide may mediate sleep induction. Nature (1997) 389:25-26.
74. DE PETROCELLIS L, MELCK D, BISOGNO T, DI MARZO V: Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders. Chem. Phys. Lipids (2000) 108:191-209.
75. BISOGNO T, MAURELLI S, MELCK D, DE PETROCELLIS L, DI MARZO V: Biosynthesis, uptake and degradation of anandamide and palmitoylethanolamide in leukocytes. J. Biol. Chem. (1997) 272:3315-3323.
76. LAMBERT DM, DI MARZO V: The palmitoylethanolamide and oleamide enigmas: are these two fatty acid amides cannabimimetic. Curr. Med. Chem. (1999) 6:757-773.
77. DI MARZO V, MELCK D, ORLANDO P et al.: Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem. J. (2001) 358:249-255.
78. MIMEAULT M,POMMERY N, WATTEZ N, BAILLY C, HENICHART JP: Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production. Prostate (2003) 56:1-12.
79. 9-Tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism. FEBS Lett. (1999) 458:400-404.
80. KAMIYAMA M, FURUYA Y, TAKIHANA Y et al: Anandamide and capsaicin inhibit proliferation of human prostate cancer cell via cannabinoid receptor and vanilloid receptor respectively. Eur. Urol. Suppl. (2003) 2:36.
81. BIFULCO M, LAEZZA C, PORTELLA G et al.: Control by die endogenous cannabinoid system of ras oncogene-dependent tumor growth. FASEB J. (2001) 15:2745-2747.
82. 1, receptor stimulation on tumor growth and metastatic spreading. actions on signals involved in angiogenesis and metastasis. FASEB J. (2003). Epublished ahead of print.
83. CASANOVA ML, BLAZQUEZ C, MARTINEZ-PALACIO J et al.: Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J. Clin. Invest. (2003) 111:43-50.
84. 2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood (2002) 100:627-634.
85. DI MARZO V, DE PETROCELLIS L, FEZZA F, LIGRESTI A, BISOGNO T: Anandamide receptors. Prostaglandins Leukot. Essent. Fatty Acids (2002) 66-377-391.
86. SMART D, GUNTHORPE MJ, JERMAN JC et al.: The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br. J. Pharmacol. (2000) 129:227-230.
87. ZYGMUNT PM, PETERSSON J, ANDERSSON DA et al.: Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature (1999) 400:452-457.
88. CATERINA MJ, SCHUMACHER MA, TOMINAGA M, ROSEN TA, LEVINE JD, JULIUS D: The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature (1997) 389:816-824.
89. MACCARRONE M, LORENZON T, BARI M, MELINO G, FINAZZI-AGRO A: Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. J. Biol. Chem (2000) 275:31938-31945.
90. JACOBSSON SO, WALLIN T, FOWLER CJ: Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. J. Pharmacol. Exp. Ther. (2001) 299:951-959.
91. SARKER KP, BISWAS KK, TAMAKUCHI M et al.: ASK1-p38 MAPK/JNK signaling cascade mediates anandamide-induced PC12 cell death. J. Neurochem. (2003) 85:50-61.
92. SARKER KP, OBARA S, NAKATA M, KITAJIMA I, MARUYAMA I: Anandamide induces opoptosis of PC-12 cells: involvement of superoxide and caspase-3. FEBS Lett. (2000) 472:39-44.
93. MACCARRONE M, ATTINA M, CARTONI A, BARI M, FINAZZI-AGRO A: Gas chromatography - mass spectrometry analysis of endogenous cannabinoids in healthy and tumoral human brain and human cells in culture. J. Neurochem. (2001) 76:594-601.
94. PAGOTTO U, MARSICANO G, FEZZA F et al.: Normal human pituitary gland and pituitary adenomas express cannabinoid receptor Type 1 and synthesize endogenous cannabinoids: first evidenee for a direct role of cannabinoids on hormone modulation at the human pituitary level. J. Clin. Endocrinol. Metab. (2001) 86:2687-2696.
95. LIGRESTI A, BISOGNO T, MATIAS I et al.: Posssible endocannabinoid control of colorectal cancer growth. Gastroenterology (2003) 125:677-687.
96. 2 receptor-mediated, cytokine-dependent pathway. J. Immunol. (2000) 165:373-380.
97. TASHKIN DR, BALDWIN GC, SARAFIAN T, DUBINETT S, ROTH MD: Respiratory and immunologic consequences of marijuana smoking. J. Clin. Pharmacol. (2002) 42:S71-S81.
98. 2. Ann. NY Acad. Sci. (2003) 996:10-16.
99. 2 transgenic mice. Exp. Hematol. (2002) 30:142-149.
100. 1 receptors. Biochem. Biophys. Res. Commun. (1999) 262:275-284.
101. DI MARZO V, BISOGNO T, MELCK D et al.: Interactions between synthetic vanilloids and the endogenous cannabinoid system. FEBS Lett. (1998) 436:449-454.